PURIFRON 5MIU Injection Vial

Frequently asked questions

• Onset of action

  The peak effect of this medicine can be observed within 3-12 hours of intramuscular or subcutaneous dose and 30 minutes followed by an intravenous administration of the dose.

• Duration of Effect

  The amount of time for which this medicine remains active in the body is not clinically established.

• Safe with Alchohol?

  Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

• Is it habit forming?

  No habit-forming tendencies were reported.

• Usage in pregnancy?

  This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

• Usage while breast-feeding?

  This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue the drug or to discontinue breastfeeding based on your clinical condition

• Allergy

  This medicine is not recommended for use in patients with a known allergy to PURIFRON 5MIU Injection Vial or any other inactive ingredients present along with it.

• Autoimmune hepatitis

  This medicine is not recommended for use in patients with autoimmune hepatitis due to the increased risk of worsening of the patient's condition.

• Decompensated Liver Disease

  This medicine is not recommended for use in patients with decompensated liver disease due to the increased risk of worsening of the patient's condition.

• Pregnancy

  This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

• Breast-feeding

  This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue the drug or to discontinue breastfeeding based on your clinical condition

• Severe allergic reactions

  This medicine may cause severe allergic reactions. In case of any such reactions, treatment should be discontinued and appropriate medical therapy should be instituted immediately.

• Psychiatric problems

  Use of this medicine can cause life-threatening or fatal neuropsychiatric reactions. These include suicide, suicidal tendency, depression, and an increased risk of relapse of recovering drug addicts. Educate the patients and their caregivers to report any symptoms of depression or suicidal tendency to the doctor so that counseling and monitoring of progress can be performed at regular intervals.

• Bone marrow suppression

  Use of this medicine can cause bone marrow depression. Severe decreases in white blood cell or platelet counts have been reported with this medicine. Close monitoring of blood cell count and symptoms for any infections should be monitored. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

• Autoimmunity

  The use of this medicine can develop different auto-antibodies in the body which may lead to various autoimmune disorders. Close monitoring of symptoms, auto-antibodies, and TSH levels are recommended.

• Growth retardation in pediatric patients

  Weight loss and growth inhibition reported during combination therapy in pediatric patients.

• Heart diseases

  This medicine should be used with caution in patients with cardiac dysfunctions such as hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure due to increased risk of worsening of the patient's condition. Close monitoring of cardiac function, appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

• Lung toxicity

  This medicine should be used with caution in patients with lung diseases since it may worsen the condition. Report any symptoms like breathing difficulty, pulmonary infiltrates, pulmonary hypertension, interstitial pneumonitis, pneumonia, bronchiolitis obliterans, etc to your doctor on priority. Close monitoring of lung function, appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

• Contraception

  Use of this medicine in combination with ribavirin may increase the risk of harm to the unborn baby in pregnant women. Effective contraception is advised for the men with female partners and women with the childbearing potential to avoid such risks. Birth controls should be administered while receiving this medicine and for 4-7 months post-therapy to prevent the pregnancy.

Administer this medicine as advised by the doctor. It should be given in multiple cycles along with other antiviral agents. It is important to receive every scheduled dose. The blood cells, liver function, CNS disorders, cardiac function, renal function should be assessed before starting the treatment. Any signs and symptoms of psychiatric, heart and liver dysfunction should be reported to the doctor on priority.

• Usage does not depend on food timings
• To be taken as instructed by doctor
• May cause sleepiness

• webmd.com - Interferon Alfa-2B [Internet]. Available from: https://www.webmd.com/drugs/2/drug-37/interferon-alfa-2b-injection/details [cited 28/7/2020].